TNFRSF17 and plasma cell myeloma: Currently, all CAR-T cell therapies approved by the United States Food and Drug Administration (FDA) remain autologous, targeting CD19-positive B-cell leukemia and lymphoma (i.e., Kymriah, Yescarta, Tecartus, and Breyanzi), as well as B-cell maturation antigen (BCMA)-positive multiple myeloma (MM) (i.e., Abecma and Carvykti).